We spent a generation chasing LDL-C. ApoB tells you what LDL-C is actually counting — and how many particles are in your arteries tonight.
If you've been measuring lipids for any length of time, you know LDL-C: low-density lipoprotein cholesterol. It is the number on the panel that doctors have asked patients about for a generation. It is also, on its own, a poor proxy for what we actually care about — the count of atherogenic particles in circulation.
ApoB — apolipoprotein B — is one molecule per particle. Measure ApoB, and you have a near-direct count of every potentially-atherogenic lipoprotein in the blood: LDL, VLDL, IDL, and Lp(a). It is the cleanest single number we have for cardiovascular risk after fifty years of cholesterol research.
Why this matters in practice
About one in three adults has a "concordant" lipid panel: LDL-C and ApoB tell the same story. For the other two thirds, they don't. A normal LDL-C with an elevated ApoB is what we call a discordance — and it is exactly the population we miss with the older marker. These are people doing everything right by LDL-C standards and still depositing plaque.
The fix is structural: we ask for an ApoB on every Long Arc Panel. We trend it. When it moves, we know what we changed. When it doesn't, we know what to change next.
What moves ApoB
Diet does meaningful work. Soluble fiber at 40g a day routinely drops ApoB 10–20 mg/dL over twelve weeks. Saturated fat reduction (capped near 10g a day) does similar. Statins do more, when needed.
Exercise, surprisingly, does less than diet on this specific marker. Sleep does almost nothing. ApoB is a plate-and-pharmacology problem more than a lifestyle problem.
If you remember one thing from this essay: ask your physician for an ApoB on your next panel, and pay attention to the trend.